department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Deoxycholic Acid · pharmadog

pharmadog
drugs
Deoxycholic Acid

drug

patient view →

deoxycholic acid

Marketedupdated 2mo ago

by Slayback Pharma LLC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Deoxycholic Acid

generic

deoxycholic acid

indication

Dermatological Disorders

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 10, 2027

~1.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

Feb 17, 2032method-of-use (U-1940)US 12161653
Mar 2, 2030formulationUS 105002143.7y
Mar 2, 2030formulationUS 81015933.7y
Mar 2, 2030formulationUS 83676493.7y
Mar 2, 2030formulationUS 86530583.7y
May 16, 2028compositionUS 82422941.9y
Feb 21, 2028formulationUS 84611401.6y
Feb 21, 2028formulationUS 85463671.6y
Feb 21, 2028formulationUS 88837701.6y
Feb 21, 2028formulationUS 95221551.6y
Feb 21, 2028method-of-use (U-1940)US 96363491.6y
Feb 21, 2028method-of-use (U-1940)US 99499861.6y
Dec 10, 2027method-of-use (U-1690)US 76221301.4y
Dec 10, 2027method-of-use (U-1690)US 77542301.4y

Data sources

ClinicalTrials.gov

last refreshed 58m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying deoxycholic acid

N/AEvaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fatcompletedn=30
phase3Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis Ccompletedn=596
N/AEffectiveness and Safety Evaluation of Embella (Deoxycholic Acid, by Espad Pharmed Co.) in Management of Submental Fatcompletedn=20
N/AEvaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomasrecruitingn=10
phase3A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)withdrawn
phase3norUrsodeoxycholic Acid vs Placebo in PSCactive not recruitingn=303
phase2Norursodeoxycholic Acid vs. Placebo in NASHunknownn=363
phase2Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)terminatedn=165

more trials →